ALTOPREV™ (Lovastatin) Extended-Release Tablets contain a cholesterol-lowering agent isolated from a strain of
Aspergillus terreus. After oral ingestion, lovastatin, which is an inactive lactone, is hydrolyzed to the corresponding (beta)-hydroxyacid form. This is a principal metabolite and inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. This enzyme catalyzes the conversion of HMG-CoA to mevalonate, which is an early and rate limiting step in the biosynthesis of cholesterol.
Therapy with ALTOPREV™ (Lovastatin) Extended-Release Tablets should be a component of multiple risk factor intervention in those individuals with dyslipidemia who are at risk for atherosclerotic vascular disease. ALTOPREV™ should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower Total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk.
ALTOPREV™ is indicated for the following:
Primary Prevention of Coronary Heart Disease
In individuals without symptomatic cardiovascular disease, average to moderately elevated Total-C and LDL-C, and below average HDL-C, ALTOPREV™ is indicated to reduce the risk of:
Coronary revascularization procedures
(See CLINICAL PHARMACOLOGY, Clinical Studies.)
Coronary Heart Disease
ALTOPREV™ is indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower Total-C and LDL-C to target levels.
Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for artherosclerotic vascular disease due to hypercholesterolemia
ALTOPREV™ is indicated as an adjunct to diet for the reduction of elevated Total-C, LDL-C, Apo B, and TG, and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and non-familial) and mixed dyslipidemia (Fredrickson types IIa and IIb, see Table VI) when the response to diet restricted in saturated fat and cholesterol and to other non-pharmacological measures alone has been inadequate.
Media Articles Related to Altoprev (Lovastatin)
Statin Drug Shows Promise For Fighting Malaria Effects
Source: Statins News From Medical News Today [2012.12.31]
Researchers have discovered that adding lovastatin, a widely used cholesterol-lowering drug, to traditional antimalarial treatment decreases neuroinflammation and protects against cognitive impairment in a mouse model of cerebral malaria...
Published Studies Related to Altoprev (Lovastatin)
Thalidomide, dexamethasone and lovastatin with autologous stem cell transplantation as a salvage immunomodulatory therapy in patients with relapsed and refractory multiple myeloma. [2011.10]
The treatment of patients with multiple myeloma usually includes many drugs including thalidomide, lenalidomide and bortezomib.Our results suggest that the addition of lovastatin to the TD regimen may improve the response rate in patients with relapsed or refractory myeloma.
Influence of one-year treatment with lovastatin on myocardial remodeling and ischemia in patients with coronary artery disease. [2011.02]
OBJECTIVE: Emerging evidence assumes that statins have a benefit to influence the myocardial remodeling and ischemia in patients with coronary artery disease (CAD). Our aim was to investigate the possible and direct favorable effects of lovastatin on left ventricular (LV) systolic, diastolic function and myocardial ischemia in patients with CAD... CONCLUSION: Lipid-lowering therapy with lovastatin improved the LV systolic function and decreased myocardial ischemia.
Pharmacokinetic interaction between oral lovastatin and verapamil in healthy subjects: role of P-glycoprotein inhibition by lovastatin. [2010.03]
BACKGROUND: Lovastatin is an inhibitor of P-glycoprotein (P-gp) and is metabolized by the cytochrome P450 (CYP) 3A4 isoenzyme. Verapamil is a substrate of both P-gp and CYP3A4. It is therefore likely that lovastatin can alter the absorption and metabolism of verapamil... CONCLUSION: Lovastatin increased the absorption of verapamil by inhibiting P-gp and inhibited the first-pass metabolism of verapamil by inhibiting CYP3A4 in the intestine and/or liver in humans.
Effect of lovastatin on primary prevention of cardiovascular events in mild CKD and kidney function loss: a post hoc analysis of the Air Force/Texas Coronary Atherosclerosis Prevention Study. [2010.01]
BACKGROUND: Chronic kidney disease (CKD) is associated with an increased risk of incident cardiovascular disease (CVD); however, the role of statins for the primary prevention of acute cardiovascular events in patients with CKD and the effect of statins on kidney function loss in persons without prevalent CVD have not been studied... CONCLUSIONS: Lovastatin is effective for the primary prevention of CVD in patients with CKD, but is not effective in decreasing kidney function loss in persons with no CVD. Copyright 2009 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.
Effect of niacin ER/lovastatin on claudication symptoms in patients with
peripheral artery disease. 
In patients with peripheral artery disease (PAD), statins may improve the
symptoms of claudication. The Intermittent Claudication Proof of Principle
(ICPOP) study tested the hypothesis that the combination of extended release
niacin plus lovastatin would improve exercise performance in patients with PAD
and claudication compared with a diet intervention...
Clinical Trials Related to Altoprev (Lovastatin)
Trial to Evaluate the Safety of Lovastatin in Individuals With Neurofibromatosis Type I (NF1) [Recruiting]
Neurofibromatosis type I (NF1) is a genetic disorder that affects approximately 1 in 3500
individuals. Half of people with NF1 inherit the condition from a parent, and half have a
new occurrence of the condition. The manifestation of NF1 is highly variable and multiple
organ systems are typically affected. Some of the more common symptoms include benign
neurofibromas, café au lait spots, Lisch nodules (tan spots on the iris of the eye). Some
individuals with NF1 also exhibit more severe associated conditions, such as optic pathway
tumors (gliomas) or bones bending or curving. Neurocognitive deficits and specific learning
disabilities occur in approximately 30 to 50% of individuals with NF1 and are regarded by
some observers and sufferers to be among the most troubling features of a disease. The most
commonly reported findings are deficits in visuoperceptual ability, motor coordination,
expressive and receptive language, and executive functioning, which requires intact
short-term memory and attention. Patients with NF1 also show a slight depression in mean IQ
scores compared to healthy adults without the disorder.
While cognitive deficits are now a widely-recognized feature of Neurofibromatosis Type 1
(NF1), the precise cause of these deficits still remain to be determined. Dr. Alcino Silva,
a co- investigator on this study, has developed an animal model of NF1 in which mice have a
specific mutation of the *NF1* gene. These mice are physically normal but show specific
learning impairments. Dr. Silva's lab found that treatment with a medication called
lovastatin, a drug typically used for high cholesterol, reversed some of the spatial
deficits seen in these animals. Lovastatin is a medication commonly used to treat high
cholesterol and has been proven to be relatively safe and tolerable in humans.
The investigators are now conducting a randomized, double-blinded, placebo- controlled,
trial of lovastatin in patients with NF1. Participants will be randomly assigned to
lovastatin or placebo and treated for approximately 14 weeks with baseline and follow-up
assessments to evaluate safety and any effects on neurocognitive test performance.
A Phase II Study of Interaction of Lovastatin and Paclitaxel For Patients With Refractory or Relapsed Ovarian Cancer [Recruiting]
Fed Bioavailability Study of Lovastatin Tablets and Mevacor Tablets [Completed]
Pre-Prostatectomy Lovastatin on Prostate Cancer [Recruiting]
To determine the dose of continuous daily oral lovastatin needed to achieve MYC [v-myc
myelocytomatosis viral oncogene homolog (avian)] down-regulation in prostatectomy specimens
in intermediate-/high-risk localized prostate cancer patients.
Lovastatin for the Treatment of Mildly Active Rheumatoid Arthritis [Recruiting]